NovoCure Limited (NVCR)
NASDAQ · Manufacturing · Surgical & medical instruments & apparatus
$15.84−$0.3600 (−2.22%) on the dayAs of the close; data may be delayed.
NVCR price, last 12 months
Key stats
- Previous close
- $16.20
- Open
- $16.39
- Day range
- $15.82 – $16.39
- 52-week range
- $9.82 – $21.45
- Volume
- 858.4K
- Avg volume (20 days)
- 1M
- Market cap
- $1.8B
Performance
1W−5.1%
1M−11.5%
3M+2.7%
6M+34.7%
YTD+22.5%
1Y+23.4%
vs S&P 500, 1Y+6.6 pts
Technicals and fundamentals
About NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- Sector
- Manufacturing
- Industry
- Surgical & medical instruments & apparatus
- Listed on
- NASDAQ
- Market cap
- $1.8B